← Leaderboards
Thomas M Ryan
University Of Alabama At Birmingham
$5,321,710
Attributed
$5,321,710
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $731.7K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$5,321,710 · 9
By mechanism
R01$4,545,875 · 2
R56$695,090 · 1
M01$80,745 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jonathan Russell Lockhart$115,911
Others in their field
Top investigators on “Thalassemia”
- Leonard I Zon · Children'S Hospital Boston$15,590,743
- Stuart H Orkin · Children'S Hospital Boston$15,494,749
- Mitchell J Weiss · Children'S Hospital Of Philadelphia$13,173,528
- Stefano Rivella · Weill Medical College Of Cornell Univ$10,978,618
- Mark Thomas Gladwin · Clinical Center$10,973,059
- Gary M Brittenham · Weill Medical Coll Of Cornell Univ$9,600,744
Research focus
ThalassemiaHematopoietic Stem CellsDesignResourcesLaboratory MouseAllogeneic Bone Marrow TransplantationMortality Vital StatisticsMouse ModelCommunitiesInduced Pluripotent Stem CellEmbryonic Stem CellMorbidity - Disease RateAutologousBackIn VitroCooley&AposConditioningGlobinAnemiaHemoglobinAdverse EffectsCell TherapyAnimal ModelAdult
Grant awards (21)
Cell Therapies for Cooley's Anemia$695,090
R56 · FY2014 · HL · contact PI
Cell Therapies for Cooley's Anemia$345,183
R01 · FY2013 · HL · contact PI
Cell Therapies for Cooley's Anemia$362,588
R01 · FY2012 · HL · contact PI
Cell Therapies for Cooley's Anemia$366,250
R01 · FY2011 · HL · contact PI
Cell Therapies for Cooley's Anemia$366,250
R01 · FY2010 · HL · contact PI
Cell Therapies for Cooley's Anemia$365,938
R01 · FY2009 · HL · contact PI
CLINICAL TRIAL: CHEMOTHERAPY, SURGICAL RESECTION AND CHEMORADIATION IN GASTRIC C$15,841
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A PHASE I/II STUDY OF TAXOTERE, OXALIPLATIN AND 5-FLUOROURACIL$10,832
M01 · FY2008 · RR · contact PI
CHEMOTHERAPY, SURGICAL RESECTION AND CHEMORADIATION IN GASTRIC CANCER$38,663
M01 · FY2007 · RR · contact PI
CHEMORADIATION WITH OXALIPLATIN AND 5-FU FOR LOCALLY ADVANCED PANCREATIC CANCER$5,918
M01 · FY2007 · RR · contact PI
Cell Therapies for Cooley's Anemia$353,981
R01 · FY2006 · HL · contact PI
ENU Mutagenesis of Gamma Globin Silencers$283,185
R01 · FY2006 · HL · contact PI
CHEMORADIATION WITH OXALIPLATIN AND 5-FU FOR LOCALLY ADVANCED PANCREATIC CANCER$2,806
M01 · FY2006 · RR · contact PI
Cell Therapies for Cooley's Anemia$435,000
R01 · FY2005 · HL
ENU Mutagenesis of Gamma Globin Silencers$290,000
R01 · FY2005 · HL
CHEMORADIATION WITH OXALIPLATIN AND 5-FU FOR LOCALLY ADVANCED PANCREATIC CANCER$6,685
M01 · FY2005 · RR
Cell Therapies for Cooley's Anemia$362,500
R01 · FY2004 · HL
ENU Mutagenesis of Gamma Globin Silencers$290,000
R01 · FY2004 · HL
Cell Therapies for Cooley's Anemia$72,500
R01 · FY2004 · HL
Cell Therapies for Cooley's Anemia$362,500
R01 · FY2003 · HL
ENU Mutagenesis of Gamma Globin Silencers in Sickle Mice$290,000
R01 · FY2003 · HL